• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pretomanid-resistant tuberculosis.

作者信息

Koehler Niklas, Andres Sönke, Merker Matthias, Dreyer Viola, John Agnieszka, Kuhns Martin, Krieger David, Choong Eva, Verougstraete Nick, Zur Wiesch Pia Abel, Wicha Sebastian G, König Christina, Kalsdorf Barbara, Sanchez Carballo Patricia M, Schaub Dagmar, Werngren Jim, Schön Thomas, Peloquin Charles A, Schönfeld Nicolas, Verstraete Alain G, Decosterd Laurent A, Aarnoutse Rob, Niemann Stefan, Maurer Florian P, Lange Christoph

机构信息

Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Parkallee 35, 23845 Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Borstel-Hamburg-Lübeck-Riems, Parkallee 1-40, 23845 Borstel, Germany; Respiratory Medicine & International Health, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany.

National and World Health Organization Supranational Reference Laboratory for Mycobacteria, Research Center Borstel, Parkallee 18, 23845 Borstel, Germany.

出版信息

J Infect. 2023 May;86(5):520-524. doi: 10.1016/j.jinf.2023.01.039. Epub 2023 Feb 2.

DOI:10.1016/j.jinf.2023.01.039
PMID:36738862
Abstract
摘要

相似文献

1
Pretomanid-resistant tuberculosis.普瑞玛胺耐药结核病
J Infect. 2023 May;86(5):520-524. doi: 10.1016/j.jinf.2023.01.039. Epub 2023 Feb 2.
2
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.贝达喹啉、普瑞马尼德以及利奈唑胺联合或不联合莫西沙星用于治疗结核病。
Lancet Respir Med. 2024 Feb;12(2):e5-e6. doi: 10.1016/S2213-2600(23)00426-5. Epub 2023 Nov 30.
3
Pretomanid in the Treatment of Patients with Tuberculosis in the United States.普瑞玛尼在美国治疗结核病患者中的应用
N Engl J Med. 2022 Sep 1;387(9):850-852. doi: 10.1056/NEJMc2119461.
4
The Implementation of a Pretomanid-Based Treatment Regimen for Multidrug-Resistant Tuberculosis: A Case Series.基于pretomanid的耐多药结核病治疗方案的实施：病例系列
Dtsch Arztebl Int. 2023 Sep 22;120(38):641-642. doi: 10.3238/arztebl.m2023.0172.
5
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.用于药物敏感和耐药结核病的贝达喹啉、普瑞玛胺、莫西沙星和吡嗪酰胺治疗方案。
Lancet Infect Dis. 2024 Sep;24(9):940-941. doi: 10.1016/S1473-3099(24)00257-3. Epub 2024 May 17.
6
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice.普托马尼德耐药性：最新的出现情况、机制及其对临床实践的意义。
Int J Antimicrob Agents. 2023 Oct;62(4):106953. doi: 10.1016/j.ijantimicag.2023.106953. Epub 2023 Aug 16.
7
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.比较硝基咪唑类药物德拉马尼和普托马尼对耐多药和广泛耐药结核病的体外活性。
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1293-1296. doi: 10.1007/s10096-019-03551-w. Epub 2019 Apr 5.
8
Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating .对具有抗分枝杆菌活性的前体药物（PA-824）衍生物进行药效团建模，针对复制和非复制期。
J Biomol Struct Dyn. 2021 Feb;39(3):889-900. doi: 10.1080/07391102.2020.1719205. Epub 2020 Jan 30.
9
Pretomanid for tuberculosis: a systematic review.吡嗪酰胺治疗结核病：系统评价。
Clin Microbiol Infect. 2022 Jan;28(1):31-42. doi: 10.1016/j.cmi.2021.08.007. Epub 2021 Aug 14.
10
The Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.色氨酸 20 号终止突变及其与结核分枝杆菌 4.5 谱系和对德拉马尼和贝达喹啉耐药性的关联。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0102622. doi: 10.1128/aac.01026-22. Epub 2022 Nov 21.

引用本文的文献

1
Current landscape of innovative drug development and regulatory support in China.中国创新药物研发与监管支持的现状
Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.
2
Clinical best practices for caring for people with expanded resistance to newer TB drugs.针对对新型结核病药物具有广泛耐药性患者的临床最佳护理实践。
IJTLD Open. 2025 Jun 13;2(6):315-323. doi: 10.5588/ijtldopen.25.0240. eCollection 2025 Jun.
3
Identification of novel leucyl-tRNA synthetase inhibitors with antibacterial activity.
具有抗菌活性的新型亮氨酰-tRNA合成酶抑制剂的鉴定。
Future Med Chem. 2025 Apr;17(7):757-765. doi: 10.1080/17568919.2025.2485673. Epub 2025 Apr 21.
4
Differential producibility analysis reveals drug-associated carbon and nitrogen metabolite expressions in Mycobacterium tuberculosis.差异可生产性分析揭示了结核分枝杆菌中与药物相关的碳和氮代谢物表达。
J Biol Chem. 2025 Mar;301(3):108288. doi: 10.1016/j.jbc.2025.108288. Epub 2025 Feb 8.
5
Long-Term Self-Administered Outpatient Parenteral Antimicrobial Therapy in the Treatment of Tuberculosis.长期自我管理的门诊胃肠外抗菌疗法治疗结核病
Drugs. 2025 Jan;85(1):87-96. doi: 10.1007/s40265-024-02122-4. Epub 2024 Dec 29.
6
Microbiota alterations in patients treated for susceptible or drug-resistant TB.接受敏感或耐药结核病治疗的患者的微生物群改变。
IJTLD Open. 2024 Aug 1;1(8):355-361. doi: 10.5588/ijtldopen.24.0325. eCollection 2024 Aug.
7
Multidrug-resistant tuberculosis.耐多药结核病。
Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
8
Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.贝达喹啉耐药性在成功治疗耐多药结核病后的出现，纳米比亚。
Emerg Infect Dis. 2024 Mar;30(3):568-571. doi: 10.3201/eid3003.240134.
9
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.甘伏伯雷，一种首创的亮氨酰 tRNA 合成酶抑制剂，用于利福平敏感型肺结核：一项 2a 期开放标签、随机试验。
Nat Med. 2024 Mar;30(3):896-904. doi: 10.1038/s41591-024-02829-7. Epub 2024 Feb 16.
10
A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis.一种用于耐多药结核病治疗中相关一线和二线抗生素治疗药物监测的单次运行高效液相色谱-质谱多重检测法
Pharmaceutics. 2023 Oct 27;15(11):2543. doi: 10.3390/pharmaceutics15112543.